Log in to save to my catalogue

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blin...

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blin...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_uu_325692

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial

About this item

Full title

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial

Publisher

England: Elsevier Ltd

Journal title

The Lancet (British edition), 2017-05, Vol.389 (10084), p.2117-2127

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background IgA nephropathy is thought to be associated with mucosal immune system dysfunction, which manifests as renal IgA deposition that leads to impairment and end-stage renal disease in 20–40% of patients within 10–20 years. In this trial (NEFIGAN) we aimed to assess safety and efficacy of a novel targeted-release formulation of budeso...

Alternative Titles

Full title

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_DiVA_org_uu_325692

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_uu_325692

Other Identifiers

ISSN

0140-6736,1474-547X

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(17)30550-0

How to access this item